Results from phase II trials of Infigratinib (BGJ398), a FGFR2 kinase inhibitor, exhibited manageable toxicity and significant clinical effect on chemotherapy-refractory cholangiocarcinoma containing FGFR2 fusions24. This evidence concerns the gene FGFR2 and cholangiocarcinoma.